{"id":"liso-cel","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurological toxicity (CAR-T-related encephalopathy syndrome)"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL509173","moleculeType":"Small molecule","molecularWeight":"976.13"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Liso-cel involves engineering a patient's T lymphocytes to express a chimeric antigen receptor (CAR) targeting CD19, a surface antigen on B cells. Once infused back into the patient, these CAR-T cells proliferate and attack CD19-positive malignant B cells. This approach is designed to induce durable remissions in B-cell hematologic malignancies by leveraging the patient's own immune system.","oneSentence":"Liso-cel is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill B cells expressing CD19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:05.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory large B-cell lymphoma"},{"name":"Relapsed or refractory chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":"Lymphoma","enrollment":65},{"nctId":"NCT07316010","phase":"PHASE2","title":"Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-01","conditions":"Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT05359211","phase":"PHASE1","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-08","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":""},{"nctId":"NCT07188558","phase":"PHASE3","title":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2026-01-12","conditions":"Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma","enrollment":400},{"nctId":"NCT03331198","phase":"PHASE1, PHASE2","title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","status":"RECRUITING","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2017-11-27","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic","enrollment":320},{"nctId":"NCT05873712","phase":"PHASE2","title":"Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome","status":"RECRUITING","sponsor":"Aseel Alsouqi","startDate":"2023-07-28","conditions":"Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT07052305","phase":"PHASE1","title":"NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-02-10","conditions":"Large B-cell Lymphoma","enrollment":24},{"nctId":"NCT05633615","phase":"PHASE2","title":"Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2023-06-12","conditions":"Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":396},{"nctId":"NCT05583149","phase":"PHASE2","title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick C. Johnson, MD","startDate":"2023-03-01","conditions":"Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL","enrollment":28},{"nctId":"NCT06357754","phase":"","title":"Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-10-06","conditions":"Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma","enrollment":50},{"nctId":"NCT04855253","phase":"PHASE1, PHASE2","title":"Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL","status":"SUSPENDED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2021-06-09","conditions":"DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":30},{"nctId":"NCT07098364","phase":"PHASE1, PHASE2","title":"ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-12-27","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":33},{"nctId":"NCT07194980","phase":"PHASE2","title":"Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-04-01","conditions":"Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":20},{"nctId":"NCT05672173","phase":"PHASE2","title":"Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-06-02","conditions":"Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":20},{"nctId":"NCT04400591","phase":"","title":"Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol","status":"AVAILABLE","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":""},{"nctId":"NCT04359784","phase":"PHASE2","title":"Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-12-27","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":27},{"nctId":"NCT05075603","phase":"PHASE1","title":"Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy","status":"COMPLETED","sponsor":"NeoImmuneTech","startDate":"2021-08-06","conditions":"Refractory Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":17},{"nctId":"NCT05621096","phase":"PHASE1","title":"Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2023-03-21","conditions":"DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma","enrollment":33},{"nctId":"NCT03575351","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-10-23","conditions":"Lymphoma, Non-Hodgkin","enrollment":184},{"nctId":"NCT03744676","phase":"PHASE2","title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2018-11-29","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Lymphoma, B-Cell","enrollment":104},{"nctId":"NCT06788639","phase":"","title":"A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-02-04","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":300},{"nctId":"NCT06788652","phase":"","title":"A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-02-04","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":300},{"nctId":"NCT06794268","phase":"","title":"A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-02-04","conditions":"Follicular Lymphoma","enrollment":300},{"nctId":"NCT05664217","phase":"PHASE2, PHASE3","title":"NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Nektar Therapeutics","startDate":"2022-12-23","conditions":"Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma","enrollment":15},{"nctId":"NCT03484702","phase":"PHASE2","title":"Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-06-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":113},{"nctId":"NCT02631044","phase":"PHASE1","title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2016-01-06","conditions":"Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma","enrollment":387},{"nctId":"NCT06205290","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-01-16","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":""},{"nctId":"NCT03483103","phase":"PHASE2","title":"Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2018-07-27","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell","enrollment":74},{"nctId":"NCT05414162","phase":"","title":"Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy","status":"UNKNOWN","sponsor":"University Hospital, Bonn","startDate":"2022-05-16","conditions":"DLBCL, Multiple Myeloma, Cytokine Release Syndrome","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lisocabtagene Maraleucel","BREYANZI","JCAR017","Breyanzi®","BMS-986387"],"phase":"phase_3","status":"active","brandName":"Liso-cel","genericName":"Liso-cel","companyName":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","companyId":"juno-therapeutics-inc-a-bristol-myers-squibb-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liso-cel is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill B cells expressing CD19. Used for Relapsed or refractory large B-cell lymphoma, Relapsed or refractory chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}